Table 4.
Pharmacokinetic parameters and relative oral bioavailability obtained after oral administration of PTX suspension in deionized water, Ms, R-Ms, P-R-Ms, and PT-R-Ms to mice through oral gavage.
| PK Parameters | Units | PTX | R-Ms | P-R-Ms | PT-R-Ms |
|---|---|---|---|---|---|
| Cmax | μg/mL | 70.69 ± 0.14 | 80.09 ± 4.01 | 141.82 ± 1.05 | 228.91 ± 11.41 |
| Tmax | h | 4 ± 0.2 | 4 ± 0.2 | 3 ± 0.15 | 2 ± 0.1 |
| AUC 0-96 | μg/mL × h | 4271.09 ± 8.4 | 4871.19 ± 8.9 | 6271.07 ± 10.7 | 7580.56 ± 11.8 |
| AUMC 0-96 | μg/mL × h2 | 442,433.01 ± 15.2 | 452,017.23 ± 15.1 | 640,134.31 ± 17.6 | 8,725,741 ± 18.90 |
| t 1/2 | h | 32.87 ± 2.2 | 38.19 ± 2.3 | 44.01 ± 3.1 | 56.91 ± 4.8 |
| MRT 0-96 | h | 54.88 ± 2.7 | 52.697 ± 2.4 | 57.01 ± 2.6 | 67.074 ± 3.3 |
| F | % | 7.5 | 9.91 | 10.17 | 17.12 |